BB
MYOV

BB Biotech’s Myovant Sciences Ltd. MYOV Stock Holding History

BB Biotech’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$85.9M Hold
3,597,882
– – 2.16% 15
2018
Q4 		$59M Buy
3,597,882
+30,000
+0.8% +$591K 1.89% 18
2018
Q3 		$94.7M Buy
3,567,882
+60,000
+2% +$1.36M 2.51% 15
2018
Q2 		$80.2M Hold
3,507,882
– – 2.32% 16
2018
Q1 		$74.6M Hold
3,507,882
– – 2.06% 16
2017
Q4 		$44.3M Buy
3,507,882
+30,000
+0.9% +$402K 1.25% 19
2017
Q3 		$53.8M Buy
3,477,882
+160,711
+5% +$1.95M 1.49% 17
2017
Q2 		$38.8M Buy
3,317,171
+14,336
+0.4% +$178K 1.19% 19
2017
Q1 		$38.8M Buy
3,302,835
+110,000
+3% +$1.26M 1.27% 19
2016
Q4 		$39.7M Buy
+3,192,835
New +$37M 1.47% 15

Other funds holding MYOV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BB Biotech's MYOV Position: Q1 2019 in Review

BB Biotech held its Myovant Sciences Ltd. (MYOV) position steady in Q1 2019 at 3,597,882 shares worth $85.9M. The position accounts for 2.16% of the portfolio, ranked #15.

BB Biotech first reported a position in MYOV in Q4 2016 and has held it in 10 quarters since. The position peaked at $94.7M in Q3 2018. 32 funds tracked by Wall St. Rank hold MYOV as of Q1 2019.

  • BB Biotech held 3,597,882 shares of Myovant Sciences Ltd. worth $85.9M as of Q1 2019.
  • BB Biotech left its Myovant Sciences Ltd. share count unchanged in Q1 2019.
  • Myovant Sciences Ltd. made up 2.16% of BB Biotech's portfolio in Q1 2019, its #15 holding.
  • BB Biotech first reported a position in Myovant Sciences Ltd. in Q4 2016 and has held it in 10 quarters since.
  • BB Biotech's Myovant Sciences Ltd. position peaked at $94.7M in Q3 2018.
  • 32 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.